Clinical Trials Directory

Trials / Conditions / Neuroendocrine Neoplasms

Neuroendocrine Neoplasms

10 registered clinical trials studyying Neuroendocrine Neoplasms — 7 currently recruiting.

StatusTrialSponsorPhase
RecruitingProspective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms
NCT07272512
Shanghai Zhongshan HospitalPhase 4
RecruitingA Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine C
NCT05963867
Boehringer IngelheimPhase 1
CompletedA Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Hea
NCT06240741
Novartis PharmaceuticalsPhase 3
RecruitingDAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by
NCT06132113
Boehringer IngelheimPhase 1
RecruitingDAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Oth
NCT05882058
Boehringer IngelheimPhase 2
Active Not RecruitingA Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerat
NCT05879978
Boehringer IngelheimPhase 1
RecruitingLu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine
NCT04086485
National Cancer Institute (NCI)Phase 1 / Phase 2
RecruitingCollection of Liquid Biopsy Samples of Neuroendocrine Neoplasms (NEN) Patients - Collection of NET (CollectNET
NCT06541080
University Hospital, Antwerp—
RecruitingLu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
NCT03206060
National Cancer Institute (NCI)Phase 2
TerminatedStudy of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-G
NCT02315625
National Cancer Institute (NCI)Phase 2